OrsoMedical

SMS Messaging Terms and Conditions

Last Updated: November 19, 2026

1. Program Description

OrsoMedical offers an SMS/text message program to users who opt in. Messages are account and service notifications: account alerts, appointment and visit reminders, and order or result-ready notifications. This is not a marketing or promotional program.

2. Consent and Opt-In

You opt in by providing your mobile number and checking the SMS consent box when you create an account or request services on orsomedical.com. By opting in, you agree to receive recurring automated text messages at the number you provide. Consent to receive text messages is not a condition of purchasing any goods or services.

3. Message Frequency

Message frequency varies and depends on your activity and account settings.

4. Message and Data Rates

Message and data rates may apply. These charges are set by your mobile carrier and are your responsibility. Check your mobile plan for details.

5. Opt-Out and Help

  • Reply STOP at any time to unsubscribe. You will receive one confirmation message and then no further messages.
  • Reply HELP for help. You may also visit orsomedical.com or contact your care team.

6. Carriers

Supported carriers include major U.S. wireless carriers. Carriers are not liable for delayed or undelivered messages. Message delivery is subject to effective transmission by your mobile carrier and is not guaranteed.

7. Privacy

No mobile information will be shared with third parties or affiliates for marketing or promotional purposes. Text messaging originator opt-in data and consent are not shared with any third parties or affiliates. Mobile information may be disclosed only to subcontractors that provide services in direct support of the messaging program (for example, our SMS delivery provider), solely for that purpose. We do not sell, rent, or lease mobile information or SMS opt-in consent to anyone.

For full details on how we handle your information, see our Privacy Policy.

8. Changes and Contact

We may update these SMS Terms from time to time by posting the revised terms on this page and updating the "Last Updated" date. Questions about the messaging program can be sent to:

OrsoMedical
Email: privacy@orsomedical.com

Latest
●GLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJM●Ashwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.com●Ferrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASH●Lion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMed●NMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJM●Resistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSM●Sage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-Analysis●Berberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP Journals●Vitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODS●Fisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMed●GLP-1 Agonists: 72-Week Lean Mass Data Confirms Leucine Protocol Necessity · NEJM●Ashwagandha KSM-66: 600mg/day Optimal Dose Confirmed — 24-RCT Meta-Analysis · Examine.com●Ferrous Bisglycinate vs. Sulfate: Equivalent Iron, Fewer GI Events — Head-to-Head RCT · ASH●Lion's Mane 1–2g/day Significantly Improves Cognitive Scores: 8-RCT Systematic Review · PubMed●NMN 500mg Phase II Trial: NAD+ Increase + Improved Muscle Strength in Adults 65–80 · NEJM●Resistance Training 3×/Week + Leucine Reduces Sarcopenia Risk 60% During GLP-1 Use · ACSM●Sage Leaf Extract: 50% Hot Flash Reduction Confirmed — ACP Meta-Analysis●Berberine 1000–1500mg Comparable to Metformin 500mg BID for Pre-Diabetes · ACP Journals●Vitamin D >40ng/mL Significantly Correlates with Higher Free Testosterone in Men · NIH ODS●Fisetin as Senolytic: First Human Dose-Escalation Study Shows Safe Cellular Clearance · PubMed